Posted: April 16, 2020
U.S. Drug Approvals: 2010 – 2020
Posted: April 16, 2020
About the authors
Related Articles
-
Tarlatamab Emerges as New Standard of Care in Second-Line SCLC, with Significant Gains in OS, PFS
-
A Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC
-
Rethinking Radiation: Adopting Hypofractionated Radiation Therapy
-
Overcoming Resistance Remains a Challenge in Targeting KRAS